Suppr超能文献

[质子治疗脉络膜黑色素瘤:斯特拉斯堡大学医学中心的解剖学和功能结果]

[Choroidal melanoma treated by protontherapy: anatomical and functional results at Strasbourg University Medical Center].

作者信息

Saleh M, Zhang J, Benichou C, Hermsdorff C, Bourcier T, Sauer A, Speeg-Schatz C, Gaucher D

机构信息

Service d'ophtalmologie, nouvel hôpital civil, CHU de Strasbourg, 1, place de l'Hôpital, BP 426, 67091 Strasbourg cedex, France; Service d'ophtalmologie, université de Franche-Comté, CHU Jean-Minjoz de Besançon, 3, boulevard Flemming, 25000 Besançon, France.

出版信息

J Fr Ophtalmol. 2013 Sep;36(7):583-8. doi: 10.1016/j.jfo.2012.08.008. Epub 2013 Jun 25.

Abstract

PURPOSE

To report anatomical and functional results of choroidal melanoma treated by protontherapy between 2001 and 2011 and to compare these with data reported in the literature.

METHODS

The present study is a retrospective review of the charts of patients presenting with choroidal melanoma, managed at Strasbourg University Medical Center between 2001 and 2011, and receiving protontherapy. Visual acuity and a complete ophthalmologic examination, including intraocular pressure, dilated fundus exam, and ultrasonography with measurement of the major diameter of the tumor, were performed prior to treatment and at various follow-up visits (every six months for five years, then once a year for ten years). The rates and timing of local complications (cataract, rubeosis, retinal detachment, neovascular glaucoma and secondary enucleation) and systemic complications (metastasis) are also reported.

RESULTS

Seventy charts were included. Mean age of the treated population was 61.4 ± 15.2 years. Male/female ratio was 1.06. Mean visual acuity, 0.55 ± 0.6 (20/67) on presentation, decreased progressively from month 42. Mean tumor thickness was 5.8 ± 2.8mm and major diameter 11.2 ± 2.9 mm. Decreased tumor thickness was noted beginning at month 12 of follow-up (Anova, P<0.0001), while major diameter remained unchanged over time (P>0.05). The risk of complications (retinal detachment, rubeosis, neovascular glaucoma) was greater between the second and third year. Mean 5-year survival was 87.5%. The rate of secondary enucleation was 8.5%.

CONCLUSION

Protontherapy most often allows for preservation of the globe. Visual loss, often significant and permanent, is frequent.

摘要

目的

报告2001年至2011年间接受质子治疗的脉络膜黑色素瘤的解剖学和功能结果,并与文献报道的数据进行比较。

方法

本研究是对2001年至2011年间在斯特拉斯堡大学医学中心接受质子治疗的脉络膜黑色素瘤患者病历的回顾性分析。在治疗前及不同随访时间(五年内每六个月一次,之后十年每年一次)进行视力检查及全面的眼科检查,包括眼压、散瞳眼底检查以及测量肿瘤最大直径的超声检查。同时报告局部并发症(白内障、虹膜红变、视网膜脱离、新生血管性青光眼和二次眼球摘除)和全身并发症(转移)的发生率及发生时间。

结果

纳入70份病历。治疗人群的平均年龄为61.4±15.2岁。男女比例为1.06。初诊时平均视力为0.55±0.6(20/67),从第42个月起逐渐下降。平均肿瘤厚度为5.8±2.8mm,最大直径为11.2±2.9mm。随访第12个月开始观察到肿瘤厚度减小(方差分析,P<0.0001),而最大直径随时间保持不变(P>0.05)。在第二年和第三年之间,并发症(视网膜脱离、虹膜红变、新生血管性青光眼)的风险更高。平均5年生存率为87.5%。二次眼球摘除率为8.5%。

结论

质子治疗大多能保留眼球。视力丧失通常严重且永久性,较为常见。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验